FY2026 EPS Estimate for RenovoRx Increased by Analyst

Key Points

• Ascendiant Capital Markets raised its FY2026 EPS estimate for RenovoRx to a loss of $0.27 per share from a previous loss estimate of $0.29, while maintaining a Buy rating and $14 price target.
• RenovoRx exceeded quarterly expectations, reporting a $0.05-per-share loss versus the $0.07 consensus estimate and revenue of $0.91 million compared with expectations of $0.70 million.
• Analyst sentiment is mixed but leans positive, with a MarketBeat consensus rating of Moderate Buy and an $8.50 target price; the stock recently traded at $2.11, near its one-year high of $2.20.

RenovoRx, Inc. (NASDAQ:RNXT - Free Report) - Investment analysts at Ascendiant Capital Markets raised their FY2026 earnings per share estimates for shares of RenovoRx in a research note issued to investors on Thursday, August 27th. Ascendiant Capital Markets analyst E. Woo now forecasts that the company will post earnings of ($0.27) per share for the year, up from their previous forecast of ($0.29). Ascendiant Capital Markets currently has a "Buy" rating and a $14.00 target price on the stock. The consensus estimate for RenovoRx's current full-year earnings is ($0.25) per share. Ascendiant Capital Markets also issued estimates for RenovoRx's Q4 2026 earnings at ($0.07) EPS, Q2 2027 earnings at ($0.06) EPS, Q3 2027 earnings at ($0.05) EPS, Q4 2027 earnings at ($0.02) EPS and FY2027 earnings at ($0.20) EPS.

RenovoRx (NASDAQ:RNXT - Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.02. RenovoRx had a negative net margin of 621.71% and a negative return on equity of 135.11%. The company had revenue of $0.91 million during the quarter, compared to analysts' expectations of $0.70 million.

Other analysts have also recently issued research reports about the company. Wall Street Zen upgraded RenovoRx from a "sell" rating to a "hold" rating in a research report on Saturday, August 15th. Weiss Ratings cut shares of RenovoRx from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday, August 18th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $8.50.

RenovoRx Stock Performance

RNXT stock opened at $2.11 on Wednesday. The stock's 50 day moving average price is $1.10 and its 200 day moving average price is $0.98. The firm has a market cap of $95.22 million, a P/E ratio of -6.81 and a beta of 1.12. RenovoRx has a 1 year low of $0.70 and a 1 year high of $2.20.

Hedge Funds Weigh In On RenovoRx

Large investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its stake in RenovoRx by 9.9% in the 2nd quarter. Geode Capital Management LLC now owns 353,603 shares of the company's stock worth $467,000 after buying an additional 31,730 shares during the last quarter. Northwestern Mutual Wealth Management Co. acquired a new position in shares of RenovoRx during the 2nd quarter valued at about $98,000. Citadel Advisors LLC purchased a new position in shares of RenovoRx during the 3rd quarter worth about $154,000. Wealthspire Advisors LLC acquired a new stake in shares of RenovoRx in the fourth quarter worth approximately $212,000. Finally, Bleichroeder LP boosted its position in shares of RenovoRx by 11.4% in the fourth quarter. Bleichroeder LP now owns 600,000 shares of the company's stock worth $504,000 after acquiring an additional 61,379 shares during the last quarter. 3.10% of the stock is currently owned by hedge funds and other institutional investors.

RenovoRx Company Profile

RenovoRx, Inc is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company's lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers.

RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source